Biosimilars fast gaining traction in Asian markets

Biosimilars are biologic medical products that are highly similar to already approved reference biologics, offering comparable safety, efficacy, and quality. Unlike generic drugs, which are chemically synthesised, biosimilars are derived from living organisms, making their development complex and highly regulated.

As healthcare costs continue to rise globally, biosimilars have emerged as a promising solution for enhancing access to affordable treatments, particularly in Asia, where a large population struggles with the high costs of biologic therapies.

Asia’s growing burden of chronic diseases, including cancer, diabetes, and autoimmune disorders, has intensified the need for cost-effective biologics. Many of these conditions require long-term treatment, often with expensive biologic drugs that place a significant financial strain on patients and healthcare systems.

Biosimilars offer a cost-effective alternative, helping to ease this burden and ensure broader access to essential treatments. With increasing government initiatives and support from healthcare organisations, biosimilars are gaining traction in Asian markets.

Furthermore, Asia is home to some of the fastest-growing economies and leading pharmaceutical manufacturing hubs. Countries like India, China, South Korea, and Japan are investing heavily in biopharmaceutical research and development, positioning themselves as global leaders in biosimilar production.

The competitive pricing of biosimilars, combined with advancements in biotechnological research and streamlined regulatory processes, has created a favourable environment for their adoption.

The rise of biosimilars also aligns with Asia’s commitment to achieving universal healthcare access and reducing the economic burden of high-cost treatments. As the biosimilar industry continues to grow, it is essential to understand its impact on healthcare affordability, regulatory frameworks, and market dynamics.

This article explores the expansion of biosimilars in Asia, their role in making healthcare more accessible, key regulatory developments, challenges faced by the industry, and future growth opportunities. By examining these aspects, we can gain insights into how biosimilars are shaping the future of healthcare in the region and beyond.

Market growth & trends
The biosimilar market in Asia has witnessed exponential growth, driven by increasing demand for biologic treatments and government initiatives to promote affordable healthcare. Several factors contribute to this expansion:

• Rising disease burden: The prevalence of chronic illnesses such as cancer and diabetes has led to an increased demand for biologic treatments.
• Patent expirations: As patents for original biologics expire, pharmaceutical companies are launching biosimilars as cost-effective alternatives.
• Government support: Countries like India, China, and South Korea are actively promoting biosimilar development through favourable policies and funding.
• Growing biopharmaceutical industry: Asia is home to a thriving biotech sector with established biosimilar manufacturers such as Biocon, Celltrion, and Shanghai Henlius.

• India: The Central Drugs Standard Control Organisation (CDSCO) oversees biosimilar approvals under the Biosimilar Guidelines (2012, revised 2016).
• China: The National Medical Products Administration (NMPA) follows stringent biosimilar evaluation guidelines (2015, revised 2019).
• Japan: The Pharmaceuticals and Medical Devices Agency (PMDA) regulates biosimilars under the 2009 Biosimilar Guidelines.
• South Korea: The Ministry of Food and Drug Safety (MFDS) has established a structured biosimilar approval framework since 2009.
• Each of these countries has developed robust regulations to ensure biosimilars maintain high safety and efficacy standards, fostering confidence among healthcare providers and patients.

• India – Biocon’s Trastuzumab Biosimilar: Biocon, a leading Indian biopharmaceutical company, developed CANMAb, a trastuzumab biosimilar for treating breast cancer. The drug costs 40% less than the original biologic, significantly improving patient access.
• China – Shanghai Henlius’ Rituximab Biosimilar: Shanghai Henlius launched HLX01, China’s first approved biosimilar for lymphoma treatment, reducing treatment costs by nearly 60 per cent.
• South Korea – Celltrion’s Infliximab Biosimilar: Celltrion’s Remsima, a biosimilar for autoimmune diseases, has gained international recognition, reinforcing South Korea’s position as a biosimilar hub.

• Complex manufacturing process: Biosimilars require sophisticated production techniques and stringent quality control.
• Regulatory hurdles: Diverse regulatory requirements across countries create market entry barriers.
• Physician and patient acceptance: Limited awareness and scepticism about biosimilars’ efficacy can slow adoption.
• Pricing pressures: While biosimilars are cheaper, pricing negotiations with governments and insurers affect profitability.

• Expansion into global markets: Asian biosimilar manufacturers can leverage their cost advantage to enter international markets.
• Advancements in biotechnology: Innovations in bioprocessing can enhance biosimilar production
• efficiency.
• Collaborations & partnerships: Joint ventures between Asian and global pharmaceutical companies can accelerate biosimilar development.

• Increased patient access: More patients can now afford biologic treatments, improving health outcomes.
• Reduced healthcare expenditure: Governments and insurance providers benefit from lower drug costs, allowing budget reallocation to other healthcare needs.
• Boosting local pharmaceutical industries: The biosimilar sector has created employment opportunities and stimulated economic growth.